ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Please try again later

Please try again later

Please try again later

Listen for free

View show details

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)
Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)
Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)
Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)
Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34)
Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16)
Case: Patient with ER-positive, HER2-negative breast cancer receives camizestrant after first-line tamoxifen (36:20)
Case: Patient with ER-positive, HER2-negative breast cancer receives elacestrant after disease progression on first-line letrozole/palbociclib (38:11)

CME information and select publications

No reviews yet